On June 29, 2026, one of the consequential hearings within the historical past of US hashish coverage, the essential DEA Administrative Legislation Choose (ALJ) listening to that might decide whether or not adult-use hashish joins state-licensed medical hashish on Schedule III of the Managed Substances Act, begins proceedings.
The listening to, set to happen in Arlington, Virginia and run till July 15, will tackle ‘whether or not the rest of marijuana, as outlined within the CSA, must be transferred from its present place on Schedule I of the listing of managed substances to Schedule III.’
Six weeks have handed because the April order reclassified state-licensed medical hashish and FDA-approved hashish drug merchandise below Schedule III. In that point, Trulieve grew to become the primary US hashish firm to listing on a serious American alternate, Glass Home Manufacturers has utilized to observe onto the NYSE, the DEA has opened a registration course of for state-licensed operators, and a bipartisan group of senators filed a brand new iteration of the SAFE Banking Act. The Meals and Drug Administration (FDA), against this, has been comparatively quiet.
Jonathan Havens, a former FDA regulator and companion at Saul Ewing who has suggested hashish purchasers for greater than a decade, informed MEDCAN24: “I’d say the exercise has undoubtedly been extra on the DEA, DOJ facet of the home than the FDA. FDA is doing much less time-sensitive work than DEA is doing proper now.”
However, he’s clear that this isn’t as a result of there may be nothing for the FDA to do ‘vis-à-vis the ultimate order’, however due to how the method has been bifurcated. The April order created relative readability on the FDA-approved drug merchandise facet. The complexity and unanswered questions sit largely on the state-regulated facet.
What has modified since April
The clearest industrial consequence of rescheduling thus far is capital markets entry. As we reported final week, Trulieve listed on the NYSE on 10 June, turning into the primary US ‘plant-touching’ hashish firm to listing on a serious American alternate, however solely after totally deconsolidating its adult-use operations.
Glass Home Manufacturers has since introduced plans to observe in its footsteps, whereas one other dozen or so corporations are making ready to uplist, however are ready for the end result of subsequent week’s ALJ listening to.
On the regulatory facet, the DEA opened a registration course of initially restricted to dispensaries, subsequently prolonged to growers and processors. That course of has generated vital curiosity and vital confusion in equal measure.
States are responding very otherwise, Havens defined: “You may have sure regulators on the market like California, and I commend them, who’re actively engaged with licensees and saying let’s see how we will bifurcate medical and adult-use licences so to make the most of these registration alternatives.
“After which you may have different states who’re saying, ‘we’re twin use, we’re not going to situation separate licences… We don’t know what to do, so we will’t do a lot that can assist you proper now.”‘
What hasn’t modified
In the meantime, for pharmaceutical drug builders looking for FDA approval, Havens means that the FDA is probably going persevering with stakeholder discussions and contemplating whether or not new steerage is important, however famous that ‘the FDA’s drug approval necessities don’t change simply because we’re speaking about hashish versus opioids or most cancers therapeutics’.
What it does change, nevertheless, is the trail to conducting the analysis vital for these approvals to be doable.
The Schedule I designation earlier than April’s order made it exceptionally troublesome to generate the medical information the FDA requires. Epidiolex, presently the one FDA-approved cannabis-derived medication, sourced its medical trial materials from the UK as a result of acquiring compliant supply materials in the US was so troublesome.
The Medical Marijuana and Cannabidiol Analysis Enlargement Act, signed in the course of the Biden administration, was supposed to resolve this situation, however Havens questions whether or not it has met these objectives.
“I used to be one of many individuals who was passionate about it, however while you drill down, you sort of ponder whether this made it simpler or more durable to check.”
Questions round whether or not state-licensed growers can now provide FDA-supervised analysis programmes, and the way the company treats botanical merchandise versus synthetically derived hashish compounds, stay open.
“It’s not at all times been the case that the FDA would say, positive, you’ll be able to analysis hashish from this grower that’s licensed by the state of Illinois or Maryland or New Jersey. Whereas I believe numerous us wish to say submit the ultimate order, it’s very straightforward now to develop a drug product, there are nonetheless a lot of challenges, much less so maybe than there have been pre-April, however there are nonetheless a lot of challenges.”
For instance, the FDA has been reluctant to sanction state-licensed growers as medical analysis suppliers due to federal illegality considerations. Havens suggests this might now start to step by step ease, ‘significantly as you get extra DEA registrations.’
Crucially, Havens believes that ‘additional reforms from the DEA or Congress’ could also be essential to meaningfully shift the legislative and regulatory and architectural analysis entry points.
One other key level of rivalry for hashish operators which will but want enter from the DEA or Congress to completely clear up is banking.
On June 25, a bipartisan group of senators refiled the SAFE Banking Act, which has repeatedly didn’t move into legislation regardless of years of makes an attempt.
“I’ve not heard of any huge banks which have stated, submit this rescheduling, that is sufficient for us to get off the sidelines,” Havens stated. The operators which have traditionally banked hashish companies have been state and native credit score unions, and that has not but modified.
“There are nonetheless obstructions alongside the trail, open entry to capital, chapter safety, mental property safety, actual property landlords.”
READ MORE…
Extra unanswered questions
For operators holding dual-use licences, the one permitted construction in states reminiscent of Maryland, following Trulieve’s bifurcation template, will not be an choice.
“Is a part of the enterprise Schedule III and a part of it Schedule I? Can all of it be Schedule III? How do you take care of dealing with of cash and being paid from these companies?” The wall, as Havens put it, has not come down.
This dynamic is a core instance of the remaining pressure between state and federal regulation. States have been regulating hashish markets for as much as 15 years, not like the federal businesses.
“I don’t assume the feds are able to be the lively day-to-day regulators of the state hashish markets. They don’t have that data capability. The states at this level know way more about hashish than I’d say the federal regulators do.”
He in contrast the problem now dealing with federal regulators to the early years of regulating tobacco, when the FDA ‘created a brand new period of regulatory legislation out of complete fabric’, a steep studying curve which will now as soon as once more be vital.
The listening to and what it may well really change
The ALJ Julius’s ruling, each time it arrives, is non-binding, and the DEA and Justice Division are free to observe it or ignore it.
What’s extra, shifting adult-use hashish to Schedule III is a way more complicated and nuanced proposition than April’s medical last order.
“Grownup use is rather a lot completely different than medical for a lot of completely different causes. Not the least of which is the Managed Substances Act. The FDA and DEA take care of medical merchandise, not with adult-use merchandise.”
If Julius recommends extending Schedule III to adult-use, the extra doubtless route ahead is a full notice-and-comment rulemaking, slower than the mechanism utilized in April, however extra resilient to authorized problem.
No matter follows shall be contested, Havens concedes: “This shall be challenged by anyone. As we’ve seen at each flip.”
Regardless of rising protests from business teams like NORML that not one pro-rescheduling or pro-cannabis celebration has been referred to as as a witness for the ALJ listening to, it seems unlikely this may change earlier than it commences.
That stated, Havens remained optimistic concerning the present momentum: “I’d prefer to be clear, I didn’t see this last order, at the very least within the framework it was offered in, coming. Dusting off the Single Conference and the supply below the Managed Substances Act to do that, it was an out-of-the-box concept. I believe it nonetheless is an out-of-the-box concept, and that’s what’s wanted on this house.”
“Hashish has been regulated in the identical approach formally because the Nineteen Seventies,’ he stated. ‘It’s like an enormous ship with a rusty rudder. It is vitally troublesome to maneuver that ship in some other route. And we’re beginning to transfer it.”
Subsequent week’s listening to, what’s in the end beneficial, and whether or not the DEA acts on it, will decide whether or not the ship retains shifting, and the way far.
On June 29, 2026, one of the consequential hearings within the historical past of US hashish coverage, the essential DEA Administrative Legislation Choose (ALJ) listening to that might decide whether or not adult-use hashish joins state-licensed medical hashish on Schedule III of the Managed Substances Act, begins proceedings.
The listening to, set to happen in Arlington, Virginia and run till July 15, will tackle ‘whether or not the rest of marijuana, as outlined within the CSA, must be transferred from its present place on Schedule I of the listing of managed substances to Schedule III.’
Six weeks have handed because the April order reclassified state-licensed medical hashish and FDA-approved hashish drug merchandise below Schedule III. In that point, Trulieve grew to become the primary US hashish firm to listing on a serious American alternate, Glass Home Manufacturers has utilized to observe onto the NYSE, the DEA has opened a registration course of for state-licensed operators, and a bipartisan group of senators filed a brand new iteration of the SAFE Banking Act. The Meals and Drug Administration (FDA), against this, has been comparatively quiet.
Jonathan Havens, a former FDA regulator and companion at Saul Ewing who has suggested hashish purchasers for greater than a decade, informed MEDCAN24: “I’d say the exercise has undoubtedly been extra on the DEA, DOJ facet of the home than the FDA. FDA is doing much less time-sensitive work than DEA is doing proper now.”
However, he’s clear that this isn’t as a result of there may be nothing for the FDA to do ‘vis-à-vis the ultimate order’, however due to how the method has been bifurcated. The April order created relative readability on the FDA-approved drug merchandise facet. The complexity and unanswered questions sit largely on the state-regulated facet.
What has modified since April
The clearest industrial consequence of rescheduling thus far is capital markets entry. As we reported final week, Trulieve listed on the NYSE on 10 June, turning into the primary US ‘plant-touching’ hashish firm to listing on a serious American alternate, however solely after totally deconsolidating its adult-use operations.
Glass Home Manufacturers has since introduced plans to observe in its footsteps, whereas one other dozen or so corporations are making ready to uplist, however are ready for the end result of subsequent week’s ALJ listening to.
On the regulatory facet, the DEA opened a registration course of initially restricted to dispensaries, subsequently prolonged to growers and processors. That course of has generated vital curiosity and vital confusion in equal measure.
States are responding very otherwise, Havens defined: “You may have sure regulators on the market like California, and I commend them, who’re actively engaged with licensees and saying let’s see how we will bifurcate medical and adult-use licences so to make the most of these registration alternatives.
“After which you may have different states who’re saying, ‘we’re twin use, we’re not going to situation separate licences… We don’t know what to do, so we will’t do a lot that can assist you proper now.”‘
What hasn’t modified
In the meantime, for pharmaceutical drug builders looking for FDA approval, Havens means that the FDA is probably going persevering with stakeholder discussions and contemplating whether or not new steerage is important, however famous that ‘the FDA’s drug approval necessities don’t change simply because we’re speaking about hashish versus opioids or most cancers therapeutics’.
What it does change, nevertheless, is the trail to conducting the analysis vital for these approvals to be doable.
The Schedule I designation earlier than April’s order made it exceptionally troublesome to generate the medical information the FDA requires. Epidiolex, presently the one FDA-approved cannabis-derived medication, sourced its medical trial materials from the UK as a result of acquiring compliant supply materials in the US was so troublesome.
The Medical Marijuana and Cannabidiol Analysis Enlargement Act, signed in the course of the Biden administration, was supposed to resolve this situation, however Havens questions whether or not it has met these objectives.
“I used to be one of many individuals who was passionate about it, however while you drill down, you sort of ponder whether this made it simpler or more durable to check.”
Questions round whether or not state-licensed growers can now provide FDA-supervised analysis programmes, and the way the company treats botanical merchandise versus synthetically derived hashish compounds, stay open.
“It’s not at all times been the case that the FDA would say, positive, you’ll be able to analysis hashish from this grower that’s licensed by the state of Illinois or Maryland or New Jersey. Whereas I believe numerous us wish to say submit the ultimate order, it’s very straightforward now to develop a drug product, there are nonetheless a lot of challenges, much less so maybe than there have been pre-April, however there are nonetheless a lot of challenges.”
For instance, the FDA has been reluctant to sanction state-licensed growers as medical analysis suppliers due to federal illegality considerations. Havens suggests this might now start to step by step ease, ‘significantly as you get extra DEA registrations.’
Crucially, Havens believes that ‘additional reforms from the DEA or Congress’ could also be essential to meaningfully shift the legislative and regulatory and architectural analysis entry points.
One other key level of rivalry for hashish operators which will but want enter from the DEA or Congress to completely clear up is banking.
On June 25, a bipartisan group of senators refiled the SAFE Banking Act, which has repeatedly didn’t move into legislation regardless of years of makes an attempt.
“I’ve not heard of any huge banks which have stated, submit this rescheduling, that is sufficient for us to get off the sidelines,” Havens stated. The operators which have traditionally banked hashish companies have been state and native credit score unions, and that has not but modified.
“There are nonetheless obstructions alongside the trail, open entry to capital, chapter safety, mental property safety, actual property landlords.”
READ MORE…
Extra unanswered questions
For operators holding dual-use licences, the one permitted construction in states reminiscent of Maryland, following Trulieve’s bifurcation template, will not be an choice.
“Is a part of the enterprise Schedule III and a part of it Schedule I? Can all of it be Schedule III? How do you take care of dealing with of cash and being paid from these companies?” The wall, as Havens put it, has not come down.
This dynamic is a core instance of the remaining pressure between state and federal regulation. States have been regulating hashish markets for as much as 15 years, not like the federal businesses.
“I don’t assume the feds are able to be the lively day-to-day regulators of the state hashish markets. They don’t have that data capability. The states at this level know way more about hashish than I’d say the federal regulators do.”
He in contrast the problem now dealing with federal regulators to the early years of regulating tobacco, when the FDA ‘created a brand new period of regulatory legislation out of complete fabric’, a steep studying curve which will now as soon as once more be vital.
The listening to and what it may well really change
The ALJ Julius’s ruling, each time it arrives, is non-binding, and the DEA and Justice Division are free to observe it or ignore it.
What’s extra, shifting adult-use hashish to Schedule III is a way more complicated and nuanced proposition than April’s medical last order.
“Grownup use is rather a lot completely different than medical for a lot of completely different causes. Not the least of which is the Managed Substances Act. The FDA and DEA take care of medical merchandise, not with adult-use merchandise.”
If Julius recommends extending Schedule III to adult-use, the extra doubtless route ahead is a full notice-and-comment rulemaking, slower than the mechanism utilized in April, however extra resilient to authorized problem.
No matter follows shall be contested, Havens concedes: “This shall be challenged by anyone. As we’ve seen at each flip.”
Regardless of rising protests from business teams like NORML that not one pro-rescheduling or pro-cannabis celebration has been referred to as as a witness for the ALJ listening to, it seems unlikely this may change earlier than it commences.
That stated, Havens remained optimistic concerning the present momentum: “I’d prefer to be clear, I didn’t see this last order, at the very least within the framework it was offered in, coming. Dusting off the Single Conference and the supply below the Managed Substances Act to do that, it was an out-of-the-box concept. I believe it nonetheless is an out-of-the-box concept, and that’s what’s wanted on this house.”
“Hashish has been regulated in the identical approach formally because the Nineteen Seventies,’ he stated. ‘It’s like an enormous ship with a rusty rudder. It is vitally troublesome to maneuver that ship in some other route. And we’re beginning to transfer it.”
Subsequent week’s listening to, what’s in the end beneficial, and whether or not the DEA acts on it, will decide whether or not the ship retains shifting, and the way far.
Hashish Legislation Sources in Poland
Discover important authorized pages about hashish cultivation, gross sales, and medical product laws in Poland. These assets will information you thru permissions, certifications, and compliance necessities.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland